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Worldwide, ~17.8 million children are estimated to have lost one or 
both parents due to HIV/AIDS.[1] In South Africa (SA) alone there 
are an estimated 3.9 million orphans, almost half of whom have lost 
one or both parents to AIDS-related diseases.[2] In 2012 the prevalence 
of orphanhood in SA was estimated at 16.9%, with orphans 3.5 times 
more likely to be HIV-positive compared with non-orphans.[3] With an 
estimated 320 000 children living with HIV in 2016, SA has the largest 
paediatric antiretroviral therapy (ART) programme in the world.[4]
Previous research indicates that social vulnerabilities including 
poverty, poor access to education, homelessness, neglect and 
abuse may result in orphans experiencing substantial barriers to 
accessing healthcare, leading to poorer treatment and developmental 
outcomes. [5-11] Furthermore, HIV-positive orphans have been shown 
to be at increased risk of delayed access to HIV care and poor ART 
adherence.[5,12-15] However, some limited data suggest that ART 
outcomes of orphans can be similar to those of non-orphans.[16-18] 
Given the high burden of combined HIV and orphanhood in SA, 
these are important problems to investigate but complicated ones to 
address, partly because orphans are such a vulnerable and difficult 
population to reach.
Objectives
To evaluate the association between orphan status (v. non-orphaned, 
matched on baseline characteristics) at ART initiation with attrition 
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Background. Limited research investigating treatment outcomes for HIV-positive orphans compared with non-orphans has shown mixed 
results, with several studies indicating that HIV-positive orphans are at greater risk of delayed access to HIV care and poor antiretroviral 
therapy (ART) adherence, while other data suggest that ART outcomes of orphans can be similar to those of non-orphans. Understanding 
the impact of orphan status on short-term ART outcomes could improve targeted intervention strategies, and subsequent long-term 
treatment and developmental outcomes, for HIV-positive infants, children and adolescents.
Objectives. To evaluate the relationship between orphan status and ART outcomes among HIV-positive infants, children and adolescents 
initiating ART at two large public sector HIV clinics in Johannesburg, South Africa.
Methods. This was a retrospective cohort study of HIV-positive children aged <18 years initiating standard first-line ART between June 
2004 and May 2013. Using propensity scores, orphans and non-orphans were matched for age, sex, World Health Organization stage 
and ART regimen. The effect of orphanhood on attrition from care (all-cause mortality and loss to follow-up) was evaluated using Cox 
proportional hazards regression analysis, and its effect on having a detectable viral load (≥400 copies/mL) at 12 months on ART using 
binomial regression analysis with modified Poisson distribution.
Results. A total of 251 (29.4%) orphans (maternal, paternal or both) and 603 (70.6%) non-orphans were included at ART initiation. 
Following multiple imputation for missing data and propensity score matching, 222 orphans and 222 non-orphans were included. Orphans 
had a median age of 8.0 years (interquartile range (IQR) 4.9 - 10.7) and non-orphans 7.4 years (IQR 4.2 - 10.2). A total of 12 (5.4%) orphans 
and 33 (14.9%) non-orphans experienced attrition from care during the first 12 months on ART (adjusted hazard ratio 0.32, 95% confidence 
interval (CI) 0.17 - 0.63). Among those alive and in care, with a viral load at 12 months on ART, 18.0% of orphans (33/183) and 14.8% of 
non-orphans (24/162) had a detectable viral load (adjusted risk ratio 1.15, 95% CI 1.04 - 1.28).
Conclusions. Orphans were less likely than non-orphans to experience attrition, but among those in care at 12 months, orphans were more 
likely to have detectable viral loads. Lower attrition among orphans may be due to their being in institutional or foster care, ensuring that 
they make their visits; however, their higher rates of non-suppression may result from lack of psychosocial support or stigma resulting in 
struggles to adhere. Additional research investigating age-specific outcomes will be important to elucidate these effects further.
S Afr Med J 2019;109(9):679-685. https://doi.org/10.7196/SAMJ.2019.v109i9.13462
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from care and viral suppression at 12 months among a sample of 
HIV-positive infants, children and adolescents attending two large 
public sector HIV clinics in Johannesburg, SA.
Methods
We conducted a retrospective analysis of prospectively collected data 
from two paediatric primary healthcare clinics in Johannesburg. Both 
sites are public sector clinics that follow the national ART treatment 
guidelines.[19-21] All HIV-positive ART-naive infants, children and 
adolescents aged <18 years who initiated a standard first-line ART 
regimen between 1 June 2004 and 31 May 2013 were included. 
Demographic and clinical information was captured using an 
electronic patient management system (TherapyEdge-HIV; Advanced 
Biological Laboratories (ABL) S.A., Luxembourg), while laboratory 
data were uploaded directly into TherapyEdge-HIV from the South 
African National Health Laboratory Service on a daily basis. To 
supplement data from electronic medical records, hard copies of 
patient medical files were reviewed.
According to the United Nations Children’s Fund (UNICEF) 
definition, an orphan is classified as a child aged <18 years who has 
lost one or both parents to any cause of death, while a double orphan 
is one who has lost both parents.[22] Baseline orphan status was defined 
as a child who had lost one or both parents prior to, or up to 6 months 
after, the date of ART initiation. A 6-month window after ART 
initiation was used to allow for passive follow-up and patient tracing 
or reporting of parent death. For the purpose of this analysis, the 
exposures of orphan v. non-orphan were considered. We used multiple 
imputation by chained equations to impute missing baseline values in 
our dataset. Baseline demographic and clinical characteristics of all 
patients were summarised and stratified by baseline orphan status, 
and we determined the association between these factors and being 
classified as an orphan using logistic regression analysis. Adjusted 
odds ratios with the corresponding 95% confidence intervals (CIs) 
are presented, and predictor variables (e.g. sex, age, nationality, year 
of ART initiation, baseline CD4+ count/percentage, World Health 
Organization (WHO) stage, tuberculosis, anaemia, weight, height, 
ART regimen and facility) were used to create a propensity score 
(Supplementary Table 1, available at http://www.samj.org.za/public/
sup/13462_table.pdf). Researchers then matched each orphan with 
one potential non-orphan using propensity score matching, within 
facility, using a Mayo Clinic SAS  macro.[23] As orphans and non-
orphans were substantially different, particularly with regard to age 
at initiation (the median age for orphans and non-orphans was 8.5 
years (interquartile range (IQR) 5.1 - 11.5) and 2.9 years (IQR 1.0 - 
7.4), respectively), greedy matching with a difference of 0.2 was used. 
Baseline CD4+ count, CD4+ percentage, haemoglobin, WHO stage 
and weight were assigned as the measurement date closest to the date 
of ART initiation within 90 days before and 7 days after treatment 
start date. Table 1 defines the immunological, disease and growth 
categories at ART initiation.
Outcomes by 12 months on ART included: (i) attrition, a composite 
outcome of all-cause mortality and loss to follow-up (LTF); and 
(ii) failure to suppress viral load. Deaths were identified by the family 
or by medical record review, and/or linkage with the SA national vital 
registration system.[24] LTF was defined as at least 3 months late for the 
last scheduled visit. Person-time accrued from ART initiation until 
the earliest of: (i) outcome of interest; (ii) transfer; (iii) completion 
of 12 months of follow-up; or (iv) dataset closure on 31 May 2014, 
at which point person-time was censored. Cox proportional hazards 
models, clustered by facility, were used to evaluate the relationship 
between orphanhood and attrition.
Failure to suppress viral load at 12 months was defined as having 
a detectable viral load (>400 copies/mL) at 12 months after ART 
initiation.[25] To allow for variation in visit timing, for patients who 
were alive and in care at 12 months after ART initiation, the viral 
load closest to 12 months (±6 months) was used in the analysis. To 
evaluate the association between orphan status and a detectable viral 
load at 12 months on ART, researchers used binomial regression 
analysis with a modified Poisson distribution, clustered by facility. 
Proportions and relative rates (RRs) of virological suppression 
were calculated among those alive and in care, with a viral load at 
12 months on ART,
Ethical approval was provided by the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand (ref. 
Table 1. Adjusted WHO categorisations of immunosuppression, staging,* anaemia and growth standards
Immunosuppression† Not significant Mild Advanced Severe
Up to 12 months of age (CD4+ percentage) >35 25 - 34 20 - 24 <20
≥12 - 59 months of age (CD4+ percentage) >25 20 - 24 15 - 19 <15
≥5 years of age (CD4+ cells/µL) >500 350 - 499 200 - 349 <200
Anaemia (haemoglobin, g/dL)‡ No anaemia Mild Moderate Severe
0 - 6 months of age No data No data No data No data
6 - 59 months of age ≥11.0 10.0 - 10.9 7.0 - 9.9 <7.0
5 - 11 years of age ≥11.5 11.0 - 11.4 8.0 - 10.9 <8.0
12 - 14 years of age ≥12.0 11.0 - 11.9 8.0 - 10.9 <8.0
Females ≥15 years of age ≥12.0 11.0 - 11.9 8.0 - 10.9 <8.0
Males ≥15 years of age ≥13.0 11.0 - 12.9 8.0 - 10.9 <8.0
Weight for age§ Normal Undernourished Severely undernourished
≤5 years of age (z-score) ≥2 SD <–2 SD <–3 SD
BMI for age§ Overweight Obese Thinness Severe thinness
5 - 19 years of age (z-score) >+1 SD >+2 SD <–2 SD <–3 SD
WHO = World Health Organization; BMI = body mass index; SD = standard deviation; ART = antiretroviral therapy.
*WHO clinical stage at ART initiation was determined either by physician classification or by conditions present at ART initiation.
†CD4+ percentage (%) and absolute (cells/µL) values as related to paediatric age and immunosuppression, adapted from the WHO’s ‘Interim WHO clinical staging of HIV/AIDS and HIV/AIDS 
case definitions for surveillance’.[30]
‡Haemoglobin levels to diagnose anaemia at sea level (g/dL), adapted from the WHO’s ‘Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity’.[31]
§Weight-for-age z-score was calculated using the WHO Child Growth Standards aged ≤5 years and BMI-for-age z-score for children and adolescents aged >5 - 19 years.[32] The severity of 
undernutrition was assessed by z-score according to the WHO classification of children,[33] with a z-score <–2 SD to ≤–3 SD for any anthropometric indices indicating undernourished and a 
z-score <–3 SD indicating severely undernourished.
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no. M110140) and the Boston University 
Institutional Review Board (ref. no. 
H-29768).
Results
A total of 1 332 children and adolescents 
were enrolled on ART during the study 
period, of whom 269 did not fit the inclusion 
criteria and 209 had unknown baseline 
orphan status – these were excluded, resulting 
in a prematched dataset of 854  patients 
(603 non-orphans and 251 orphans, Fig. 1). 
Propen sity score matching using predictor 
variables resulted in 222 orphans being 
matched with 222 non-orphans, with a 
similar age distribution between the two 
groups (Table 2 and Supplementary Fig. 1 – 
Supplementary Fig. 1 is available at http://
www.samj.org.za/public/sup/13462_table.
pdf). Patients contri buted 421 years of 
person-time during the 12-month follow-
up period (orphans 217, non-orphans 204, 
Table 3). The majority (94.6% of orphans, 
85.1% of non-orphans) were still on ART 
after 12 months, but 12 orphans (5.4%) and 
33 non-orphans (14.9%) were lost to care 
(died or LTF).
In crude Cox proportional hazard models 
(cHR), orphans had a reduced risk of 
attrition after 12 months on ART compared 
with non-orphans (cHR 0.32, 95% CI 0.17 - 
0.63) (Table 4). The time period of ART 
initiation also appeared to have an effect 
on attrition, with those who initiated ART 
during the later years being at a reduced 
risk of 12-month attrition (cHR 0.09, 95% 
CI 0.01 - 0.79 for June 2012 - May 2013 
compared with June 2004 - May 2006). In a 
model adjusted for period of ART initiation 
(>10% change in estimate), baseline CD4+ 
and anaemia (under-matching), orphans 
were still less likely to experience attrition 
(adjusted hazard ratio 0.32, 95% CI 0.17 - 
0.63).
Among those alive and in care, with a viral 
load at 12 months on ART (77.7%, 345/444), 
18.0% of orphans (33/183) and 14.8% of 
non-orphans (24/162) had a detectable viral 
load (>400 copies/mL). This did not differ 
by age group (p=0.7365). Crude analysis 
showed that orphans had an increased risk 
of a detectable viral load at 12 months 
after initiation of ART compared with 
non-orphans (crude risk ratio (cRR) 1.22, 
95% CI  1.12 - 1.32, Table 4). Additionally, 
those with a high or moderate CD4+ count/
percentage at baseline were 74% and 26% 
more likely to have a detectable viral load 
at 12 months, respectively, compared with 
those with a very low baseline CD4+. Those 
at WHO stage III/IV at ART initiation were 
less likely to have a detectable viral load 
compared with those at WHO stage I/II 
(cRR 0.74, 95% CI 0.64 - 0.87). Similarly, those 
with below-normal baseline anthropometric 
measurements had a lower risk of having a 
detectable viral load at 12 months than those 
with normal measurements (cRR 0.67, 95% 
CI 0.47 - 0.95). Compared with those who 
initiated ART on a non-stavudine-based 
regimen, those who initiated on a stavudine-
based regimen were less likely to have a 
detectable viral load at 12 months after ART 
initiation (cRR 0.48, 95% CI 0.39 - 0.59). 
Similarly, patients who initiated ART in the 
later years of the study were less likely to 
have a detectable viral load compared with 
those who initiated ART in the first 2 years. 
Lastly, in crude analyses, patients were 45% 
less likely to have a detectable viral load 
at site B compared with site A. In a model 
adjusted for tuberculosis at ART initiation 
(>10% in effect estimate), baseline CD4+ 
and anaemia (under-matching), baseline 
WHO stage, anthropometric measurements 
and facility (significant in crude analyses), 
orphans were still more likely to have a 
detectable viral load at 12 months on ART 
(adjusted risk ratio (aRR) 1.15, 95% CI 1.04 - 
1.28), with participants at site B less likely to 
do so than those at site A (aRR 0.75, 95% 
CI 0.61 - 0.94).
Discussion
In this matched cohort of 444 infants, 
children and adolescents in SA, we observed 
that 5.4% of orphans and 14.9% of non-
Children and adolescents enrolled




Initiated on an ART regimen 
at the study sites
n=1 083
Not initiated on a 
standard ART regimen
n=20
Met inclusion criteria, n=1 063
• Orphans, n=251 (23.3%)
• Non-orphans, n=603 (56.9%)
• Unknown orphan status at baseline, 
   n=209 (19.8%)
Excluded prior to matching, as their 
orphan status was unknown at baseline
n=209
Included in matching, n=854
• Orphans, n=251 (29,4%)
• Non-orphans, n=603 (70.6%)
Propensity score matching on 
nationality, facility, sex, baseline age, 
baseline CD4+ count/percentage, 
baseline TB, baseline Hb, 
baseline WHO stage, 
baseline weight and height, 
NRTI and being on a PI-based
rst-line regimen
Matched sample, n=444
• Orphans, n=222 (50.0%)
• Non-orphans, n=222 (50.0%)
Fig. 1. Cohort profile of children and adolescents initiating ART at one of two study sites in Johannesburg, 
SA. (ART = antiretroviral therapy; SA = South Africa; TB = tuberculosis; Hb = haemoglobin; WHO = 
World Health Organization; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.)
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Table 2. Clinical and demographic characteristics at ART initiation stratified by orphan status in HIV-positive children and 
adolescents initiating ART in Johannesburg, SA, after propensity score matching (N=444)
Non-orphans (N=222) Orphans (N=222)
Sex, n (%)
Female 115 (51.8) 110 (49.6)
Male 107 (48.2) 112 (50.5)
Age at initiation (years), n (%)
≤1 9 (4.1) 11 (5.0)
>1 - ≤5 58 (26.1) 50 (22.5)
>5 - ≤10 95 (42.8) 99 (44.6)
>10 60 (27.0) 62 (27.9)
Time period of ART initiation, n (%)
June 2004 - May 2006 12 (5.4) 15 (6.8)
June 2006 - May 2008 48 (21.6) 45 (20.3)
June 2008 - May 2010 72 (32.4) 74 (33.3)
June 2010 - May 2012 60 (27.0) 65 (29.3)
June 2012 - May 2013 30 (13.5) 23 (10.4)
CD4+ measurement* at ART initiation, n (%)
Severe 95 (42.8) 85 (38.3)
Advanced 51 (23.0) 56 (25.2)
Mild 28 (12.6) 35 (15.8)
Not significant 48 (21.6) 46 (20.7)
WHO clinical stage at ART initiation, n (%)
I or II 138 (62.2) 145 (65.3)
III or IV 84 (37.8) 77 (34.7)
TB at ART initiation, n (%)
Yes 45 (20.3) 44 (19.8)
No 177 (79.7) 178 (80.2)
Anaemia at ART initiation, n (%)
None 79 (35.6) 95 (42.8)
Mild 47 (21.2) 45 (20.3)
Moderate/severe 96 (43.2) 82 (36.9)
Weight for age at ART initiation, n (%)
Normal (WAZ ≥–2 SD) 51 (76.1) 48 (78.7)
Undernourished (WAZ <–2 to ≥–3 SD) 9 (13.4) 8 (13.1)
Severely undernourished (WAZ <–3 SD) 5 (7.5) 5 (8.2)
Missing 2 (3.0) 0 (00)
BMI for age at ART initiation, n (%)
Overweight or obese (ZBA >1 SD) 7 (4.5) 8 (5.0)
Normal weight (ZBA –2 to 1 SD) 68 (43.9) 64 (39.8)
Thinness (ZBA <–2 SD) 14 (9.0) 18 (11.2)
Severe thinness (ZBA <–3 SD) 29 (18.7) 36 (22.4)
Missing 37 (23.9) 35 (21.7)
Baseline ART regimen, n (%)
NRTI
ABC 80 (36.0) 76 (34.2)
TDF 6 (2.7) 4 (1.8)
d4T 136 (61.3) 142 (64.0)
PI†
No 201 (90.5) 195 (87.8)
Yes 21 (9.5) 27 (12.2)
Site, n (%)
Site A 35 (15.8) 35 (15.8)
Site B 187 (84.2) 187 (84.2)
Continued ...
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orphans had either died or been LTF, while 18.0% of orphans and 
14.8% of non-orphans alive and in care after 12 months on ART had 
a detectable viral load. With regard to retention in care, orphans fared 
better than their non-orphan counterparts, with orphans having 
a 68% reduction in attrition. However, among those still in care at 
12 months, orphans were 15% more likely than non-orphans to have 
a detectable viral load.
Data on outcomes of HIV-positive orphans v. non-orphans are 
sparse, with mixed results. Orphan status was not associated with 
death in a study in Kenya, while research in India concluded 
that orphans did not have worse outcomes than non-orphans.[16,17] 
Furthermore, a multicountry study in Asia found that post-ART 
mortality and retention did not differ by orphan status. However, 
orphans were at a greater risk of starting ART at older ages, and 
with more severe immunosuppression and poor growth.[18] Similar 
to our results, a Cambodian study reported that orphans had an 
increased risk of virological failure compared with non-orphans; the 
authors reflected that this worse outcome was likely to be due to poor 
adherence, which may well be the case in the present study.[26] As 
we did not measure adherence, we cannot state this with certainty; 
however, studies in Kenya and Rwanda have shown that double 
orphans are at higher risk of non-adherence to ART compared with 
single orphans and non-orphans.[12,16]
Prior to matching, and similar to other studies, orphans initiating 
ART were clinically different to non-orphans, with orphans presenting 
at an older age as well as being slightly healthier than non-orphans, 
probably because they were older.[14,16-18] Reasons for late presentation 
for clinical care may include parental illness delaying care-seeking 
for children, and that stigma around parental health and death could 
result in reluctance to access healthcare for the whole family. Parental 
death may also delay care owing to new caregivers not knowing 
the child’s HIV status, or the general chaos of family transitions.[27] 
Survey data that looked at both orphanhood and co-residence with 
a chronically ill or HIV-positive adult offer insight into possible 
reasons for these results.[27,28] The researchers hypothesise that part of 
the explanation for orphans doing better than non-orphans lies in the 
possibility that some of the orphans are in residential or alternative 
care settings.[28] Orphans are more likely than non-orphans to be in 
formalised care and this may lead to better retention; however, it is 
difficult to hypothesise why retention might be improved, but viral 
suppression is worse. Further work should be done to investigate 
outcomes of orphans in formal care settings compared with those 
who are non-institutionalised.
Study limitations
Our study has several limitations. Firstly, the fact that baseline orphan 
status was collected retrospectively, while other clinical data were 
collected prospectively, may have resulted in some misclassification. 
Twenty percent of patients who did not have baseline orphan status 
were excluded, and it is possible that documentation of orphan 
status was better among orphans who were healthier or getting 
better care. This potential bias was mitigated by reviewing the 
entire medical record and corroborating orphans’ status at baseline 
with caregiver records throughout the file. Our data also did not 
include detailed information on the primary caregivers of the 
children and adolescents (including their HIV status), children’s 
nutritional status, height for age, ART adherence and indicators of 
socioemotional or cognitive development, which may have helped in 
Table 2. (continued) Clinical and demographic characteristics at ART initiation stratified by orphan status in HIV-positive 
children and adolescents initiating ART in Johannesburg, SA, after propensity score matching (N=444)
Non-orphans (N=222) Orphans (N=222)
Age at ART initiation (years), median (IQR) 7.4 (4.2 - 10.2) 8.0 (4.9 - 10.7)
CD4+ absolute count‡ (cells/µL) at ART initiation, median (IQR) 258 (127 - 511) 274 (126 - 465)
CD4+ percentage‡ (%) at ART initiation , median (IQR) 16.8 (13.0 - 19.8) 15.5 (11.7 - 21.9)
Haemoglobin (g/dL) at ART initiation, median (IQR) 10.9 (9.9 - 11.8) 11.2 (10.3 - 12.0)
Weight for age§ at ART initiation (z-score), median (IQR) –1.1 (–1.9 - –0.6) –1.1 (–1.9 - –0.2)
BMI for age§ at ART initiation (z-score), median (IQR) –1.3 (–2.9 - –0.5) –1.6 (–3.2 - –0.3)
ART = antiretroviral therapy; SA = South Africa; WHO = World Health Organization; TB = tuberculosis; WAZ = weight-for-age z-score; BMI = body mass index; ZBA = BMI-for-age z-score;  
SD = standard deviation; NRTI = nucleoside reverse transcriptase inhibitor; ABC = abacavir; TDF = tenofovir; d4T = stavudine; PI = protease inhibitor; LPV/r = lopinavir/ritonavir;  
IQR = interquartile range.
*CD4+ classification as follows: (i) severe if children aged ≤12 months had a CD4+ percentage <20%, children aged 13 - 59 months had a CD4+ percentage <15%, or children and adolescents 
aged ≥5 years had a CD4+ count <200 cells/µL; (ii) advanced if children aged ≤12 months had a CD4+ percentage of 20 - 24%, children aged 13 - 59 months had a CD4+ percentage of 15 - 19%, 
or children and adolescents aged ≥5 years had a CD4+ count of 200 - 349 cells/µL; (iii) mild if children aged ≤12 months had a CD4 percentage of 25 - 34%, children aged 13 - 59 months had 
a CD4+ percentage of 20 - 24%, or children and adolescents aged ≥5 years had a CD4+ count of 350 - 499 cells/µL; and (iv) not significant if children aged ≤12 months had a CD4+ percentage 
>35%, children aged 13 - 59 months had a CD4+ percentage >25%, or children and adolescents aged ≥5 years had a CD4+ count >500 cells/µL.
†PI for all was LPV/r.
‡CD4+ percentage was calculated for children aged <5 years, and CD4+ absolute count for children and adolescents aged ≥5 years.
§Weight for age was calculated for children aged ≤5 years, and BMI for age for children and adolescents aged >5 years.
Table 3. Retention, attrition and immunological status at ART initiation stratified by orphan status in HIV-positive children and 
adolescents of all ages initiating ART in Johannesburg, SA, after propensity score matching (N=444)
  Total (N=444), n/N (%) Orphans (N=222), n/N (%) Non-orphans (N=222), n/N (%) 
Person-time contributed (years) 421 217 204
Alive in care at 12 months on ART 399/444 (89.9) 210/222 (94.6) 189/222 (85.1)
Viral load suppressed*,† 288/345 (83.5) 150/183 (82.0) 138/162 (85.2)
Viral load not suppressed*,† 57/345 (16.5) 33/183 (18.0) 24/162 (14.8)
Died 6/444 (1.4) 1/222 (0.5) 5/222 (2.3)
LTF 39/444 (8.8) 11/222 (5.0) 28/222 (12.6)
Attrition 45/444 (10.1) 12/222 (5.4) 33/222 (14.9)
ART = antiretroviral therapy; SA = South Africa; LTF = lost to follow-up.
*The closest viral load to 12 months following ART initiation within a 6-month window either side of 12 months after initiation (i.e. 6 - 18 months post ART initiation).
†27 orphans and 27 non-orphans who were alive and in care at 12 months did not have a viral load result within the 12-month window and are excluded from the suppression analysis.
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Table 4. Unadjusted and adjusted estimates of the relation between baseline orphan status and attrition (all-cause mortality and 
LTF) and viral suppression at 12 months on ART
Characteristic
                     Attrition (N=444)
 
Failure to suppress viral load* (N=345)
n/N (%) aHR (95% CI) n/N (%) aRR (95% CI)
Orphan status at initiation      
Non-orphan 33/222 (14.9) 1.00 24/162 (14.8) 1.00
Orphan 12/222 (5.4) 0.32 (0.17 - 0.63) 33/183 (18.0) 1.15 (1.04 - 1.28)
Sex
Female 23/225 (10.2) 29/173 (16.8)
Male 22/219 (10.1) 28/172 (16.3)
Age at initiation (years)
≤1 1/20 (5.0) 4/18 (22.2)
>1 - ≤5 18/108 (16.7) 9/77 (11.7)
>5 - ≤10 15/194 (7.7) 20/161 (12.4)
>10 11/122 (9.0) 24/89 (27.0)
Time period of ART initiation
June 2004 - May 2006 5/27 (18.5) 1.00 4/16 (25.0)
June 2006 - May 2008 7/93 (7.5) 0.30 (0.10 - 1.00) 6/83 (7.2)
June 2008 - May 2010 14/146 (9.6) 0.42 (0.15 - 1.19) 16/125 (12.8)
June 2010 - May 2012 18/125 (14.4) 0.70 (0.26 - 1.89) 25/102 (24.5)
June 2012 - May 2013 1/53 (1.9) 0.08 (0.01 - 0.69) 6/19 (31.6)
Baseline CD4+ classification†
Severe 25/180 (13.9) 1.00 19/138 (13.8) 1.00
Advanced 7/107 (6.5) 0.46 (0.20 - 1.08) 13/82 (15.9) 0.91 (0.53 - 1.57)
Mild 4/63 (6.4) 0.44 (0.15 - 1.27) 12/50 (24.0) 2.09 (1.73 - 2.52)
Not significant 9/94 (9.6) 0.71 (0.33 - 1.53) 13/75 (17.3) 1.05 (0.93 - 1.18)
Anaemia at ART initiation
None 16/174 (9.2) 1.00 23/141 (16.3)
Mild 11/92 (12.0) 1.34 (0.62 - 2.89) 11/65 (16.9) 1.05 (0.96 - 1.15)
Moderate/severe 18/178 (10.1) 0.96 (0.49 - 1.90) 23/139 (15.6) 1.05 (0.80 - 1.40)
TB at ART initiation
No 35/355 (9.9) 46/269 (17.1) 1.00
Yes 10/89 (11.2) 11/76 (14.5) 0.91 (0.75 - 1.11)
WHO stage at initiation
I/II 29/283 (103) 39/213 (18.3) 1.00
III/IV 16/161 (9.9) 18/132 (13.6) 1.00 (0.70 - 1.41)
Anthropometric measurements‡
Normal/above normal 36/246 (14.6) 36/168 (21.4) 1.00
Below normal 5/59 (8.5) 7/49 (14.2) 0.70 (0.46 - 1.06)
Missing 4/139 (2.9) 14/128 (10.9)
NRTI in first regimen
Non-d4T based 16/166 (9.6) 29/114 (25.4)
d4T 29/278 (10.4) 28/231 (12.1)
PI in first regimen
No 42/396 (10.6) 50/305 (16.4)
Yes 3/48 (6.3) 7/40 (17.5)
Site
A 7/70 (10.0) 14/52 (26.9) 1.00
B 38/374 (10.2) 43/293 (14.7) 0.75 (0.61 - 0.94)
LTF = loss to follow-up; ART = antiretroviral therapy; aHR = adjusted hazard ratio; aRR = adjusted risk ratio; CI = confidence interval; TB = tuberculosis; WHO = World Health Organization; 
NRTI = nucleoside reverse transcriptase inhibitor; d4T = stavudine; PI = protease inhibitor; SD = standard deviation; BMI = body mass index.
*Among those with a viral load at 12 months.
†CD4+ classification as follows: (i) severe if children aged ≤12 months had a CD4+ percentage <20%, children aged 13 - 59 months had a CD4+ percentage <15%, or children and adolescents 
aged ≥5 years had a CD4+ count <200 cells/µL; (ii) advanced if children aged ≤12 months had a CD4+ percentage of 20 - 24%, children aged 13 - 59 months had a CD4+ percentage of 15 - 19%, 
or children and adolescents aged ≥5 years had a CD4+ count of 200 - 349 cells/µL; (iii) mild if children aged ≤12 months had a CD4 percentage of 25 - 34%, children aged 13 - 59 months had 
a CD4+ percentage of 20 - 24%, or children and adolescents aged ≥5 years had a CD4+ count of 350 - 499 cells/µL; and (iv) not significant if children aged ≤12 months had a CD4+ percentage 
>35%, children aged 13 - 59 months had a CD4+ percentage >25%, or children and adolescents aged ≥5 years had a CD4+ count >500 cells/µL.
‡Normal or above normal defined as weight-for-age z-score for children ≤5 years of age ≥–2 SD or BMI-for-age z-score for children and adolescents >5 years of age ≥–2 SD; below normal defined 
as weight-for-age z-score for children ≤5 years of age <–2 SD or BMI-for-age z-score for children and adolescents >5 years of age <–2 SD.
All baseline characteristics that resulted in a ≥±10% change in the effect of orphan status were included in the respective adjusted models. Additionally, potential confounders that had not 
balanced during the matching process were included in the adjusted models.
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understanding the reasons for better attrition outcomes for orphans. 
This analysis only investigated short-term outcomes, resulting in 
small outcome numbers; longer follow-up may have elucidated 
additional information. Furthermore, the linkage in the national 
death register is poor for children, with only an estimated 42% of 
deaths that occurred under the age of 1 year recorded in 2007. [29] 
As such, it is likely that deaths are under-recorded, resulting in 
underestimation of mortality. Additionally, the researchers could not 
link the infant, child or adolescent file to parent files to verify parental 
vital status, resulting in inability to link parents to the death registry 
to verify orphan status. These data were only from two non-randomly 
selected urban sites, so results cannot be generalised to children 
accessing care in non-urban settings.
This study highlights the challenges in conducting outcomes 
research in clinical settings. There was probably patient self-selection, 
resulting in our data only comprising children with sufficient family 
or institutional support to get to care; it is possible that some HIV-
positive orphans do not even make it into care before dying, and 
the ones who do may be healthier, resulting in skewed populations 
with regard to baseline differences. This possible selection bias may 
have led to uncontrolled confounding, making it difficult to say 
whether this bias would be different for orphans v. non-orphans in 
the general population, as the characteristics of those who did not 
initiate ART are not known. Despite this, the researchers believe that 
this clinic-based study still adds to the evidence base and can provide 
valuable insight for future programming, including highlighting 
possible predictors of poor treatment outcomes, allowing for targeted 
early engagement of children and caregivers at initial HIV care and 
treatment visits.
Conclusions
Our results show that, once on ART, orphans were less likely than 
non-orphans to be lost to care (die or be LTF). This result may be 
because orphans are more integrated into care owing to orphan-
specific programming or foster care, or because the orphans in this 
study were systematically different to the non-orphans in a way 
that did not allow for the removal of all bias. Understanding the 
impact of orphan status on ART outcomes could improve targeted 
strategies, and subsequent treatment and developmental outcomes, 
for HIV-positive  infants, children and adolescents. Additional 
research investigating age-specific outcomes as well as care-setting 
environments and the role of the caretaker will be important to 
elucidate these effects further.
Declaration. None.
Acknowledgements. The authors thank the patients and staff at the two 
study sites for making this work possible.
Author contributions. Conceptualised the study: DE; analysed the data: 
CH, ATB; wrote the manuscript: CH, DE; reviewed the manuscript: CH, 
DE, ATB, SP, SU, JB, LL, IS, MPF.
Funding.  This study has been made possible by the generous support 
of the American people and the President’s Emergency Plan for AIDS 
Relief (PEPFAR) through the United States Agency for International 
Development (USAID)  under the terms of the Cooperative Agreement 
674-A-00-08-0000-700 to Right to Care and Cooperative Agreements 
AID-674-A-12-00029 and 72067419CA00004  to the Health Economics 
and Epidemiology Research Office. The contents are the responsibility of 
the authors and do not necessarily reflect the views of PEPFAR, USAID, 
the United States Government or the Right to Care Clinics.
Conflicts of interest. None.
1. United Nations Children’s Fund (UNICEF). Towards an AIDS-free generation: Children and AIDS: 
Sixth Stocktaking Report, 2013. https://www.unicef.org/publications/files/Children_and_AIDS_Sixth_
Stocktaking_Report_EN.pdf  (accessed 25 January 2019).
2. United Nations Children’s Fund (UNICEF) South Africa. Biennial Report South Africa 2016. https://
www.unicef.org/southafrica/SAF_resources_biennialreport2014_2015.pdf  (accessed 25 January 2019).
3. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence and Behaviour 
Survey, 2012. Cape Town: Human Sciences Research Council, 2014. http://www.hsrc.ac.za/uploads/
pageContent/4565/SABSSM%20IV%20LEO%20final.pdf  (accessed 25 January 2019).
4. Joint United Nations Programme on HIV and AIDS (UNAIDS). UNAIDS country factsheets: South Africa 
2016. http://www.unaids.org/en/regionscountries/countries/southafrica (accessed 25 January 2019).
5. Amoako Johnson F, Padmadas SS, Smith PW. Orphanhood and vulnerability: A conduit to poor child 
health outcomes in Rwanda. AIDS Care 2010;22(3):314-323. https://doi.org/10.1080/09540120903193682
6. Andrews G, Skinner D, Zuma K. Epidemiology of health and vulnerability among children orphaned 
and made vulnerable by HIV/AIDS in sub-Saharan Africa. AIDS Care 2006;18(3):269-276. https://doi.
org/10.1080/09540120500471861
7. Govender K, Reardon C, Quinlan T, George G. Children’s psychosocial wellbeing in the context of HIV/
AIDS and poverty: Á comparative investigation of orphaned and non-orphaned children living in South 
Africa. BMC Public Health 2014;14:615. https://doi.org/10.1186/1471-2458-14-615
8. Hallfors DD, Cho H, Rusakaniko S, et al. The impact of school subsidies on HIV-related outcomes 
among adolescent female orphans. J Adolesc Health 2015;56(1):79-84. https://doi.org/10.1016/j.
jadohealth.2014.09.004
9. Kaggwa EB, Hindin MJ. The psychological effect of orphanhood in a matured HIV epidemic: An analysis 
of young people in Mukono, Uganda. Soc Sci Med 2010;70(7):1002-1010. https://doi.org/10.1016/j.
socscimed.2009.12.002
10. Marais L, Sharp C, Pappin M, et al. Community-based mental health support for orphans and vulnerable 
children in South Africa: A triangulation study. Vulnerable Child Youth Stud 2014;9(2):151-158. https://
doi.org/10.1080/17450128.2013.855345
11. Meghdadpour S, Curtis S, Pettifor A, MacPhail C. Factors associated with substance use among orphaned 
and non-orphaned youth in South Africa. J Adolesc 2012;35(5):1329-1340. https://doi.org/10.1016/j.
adolescence.2012.05.005
12. Kikuchi K, Poudel KC, Muganda J, et al. High risk of ART non-adherence and delay of ART initiation 
among HIV positive double orphans in Kigali, Rwanda. PloS One 2012;7(7):e41998. https://doi.
org/10.1371/journal.pone.0041998
13. Kikuchi K, Poudel KC, Muganda J, et al. What makes orphans in Kigali, Rwanda, non-adherent to 
antiretroviral therapy? Perspectives of their caregivers. J Int AIDS Soc 2014;17:19310. https://doi.
org/10.7448/IAS.17.1.19310
14. Mokgatle MM, Madiba S. The burden of disease on HIV-infected orphaned and non-orphaned children 
accessing primary health facilities in a rural district with poor resources in South Africa: A cross-
sectional survey of primary caregivers of HIV-infected children aged 5 - 18 years. Infect Dis Poverty 
2015;4:18. https://doi.org/10.1186/s40249-015-0049-x
15. Ntanda H, Olupot-Olupot P, Mugyenyi P, et al. Orphanhood predicts delayed access to care in Ugandan 
children. Pediatr Infect Dis J 2009;28(2):153-155. https://doi.org/10.1097/INF.0b013e318184eeeb
16. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned 
children on antiretroviral therapy in western Kenya. J Acquir Immune Deficienc Syndr 2006;43(4):418-
425. https://doi.org/10.1097/01.qai.0000243122.52282.89 
17. Bhattacharya M, Saxena R. Outcome of anti-retroviral treatment in HIV-infected orphans and non-
orphans at an ART centre in North India. Paediatr Int Child Health 2012;32(4):228-232. https://doi.
org/10.1179/2046905512Y.0000000035
18. Huy BV, Teeraananchai S, Oanh LN, et al. Impact of orphan status on HIV treatment outcomes 
and retention in care of children and adolescents in Asia. J Virus Erad 2016;2(4):227-231. http://
viruseradication.com/journal-details/Impact_of_orphan_status_on_HIV_treatment_outcomes_and_
retention_in_care_of_children_and_adolescents_in_Asia/ (accessed 4 February 2019).
19. National Department of Health, South Africa. National Antiretroviral Treatment Guidelines. 2004. http://
apps.who.int/medicinedocs/documents/s17758en/s17758en.pdf  (accessed 25 January 2019).
20. National Department of Health, South Africa. South African Antiretroviral Treatment Guidelines 2010. 
2010. http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf  (accessed 25 January 2019).
21. National Department of Health, South Africa. South African Antiretroviral Treatment Guidelines 
2013. 2013. https://sahivsoc.org/Files/2013%20ART%20Treatment%20Guidelines%20Final%2025%20
March%202013%20corrected.pdf  (accessed 25 January 2019).
22. United Nations Children’s Fund (UNICEF). Orphans. https://www.unicef.org/media/media_45279.html 
(accessed 25 January 2019).
23. Mayo Clinic. Division of Biomedical Statistics and Informatics. GMATCH. http://bioinformaticstools.
mayo.edu/research/gmatch/ (accessed 10 July 2019).
24. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality 
among patients lost to follow-up from ART programmes: Evidence from the Themba Lethu Clinic, South 
Africa. Trop Med Int Health 2010;15(4):405-413. https://doi.org/10.1111/j.1365-3156.2010.02473.x
25. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on 
antiretroviral treatment: A retrospective analysis at a large public sector HIV clinic in South Africa. J Int 
AIDS Soc 2010;13:49. https://doi.org/10.1186/1758-2652-13-49
26. Raguenaud ME, Isaakidis P, Zachariah R, et al. Excellent outcomes among HIV+ children on ART, but 
unacceptably high pre-ART mortality and losses to follow-up: A cohort study from Cambodia. BMC 
Pediatr 2009;9:54. https://doi.org/10.1186/1471-2431-9-54 
27. Magadi MA. Household and community HIV/AIDS status and child malnutrition in sub-Saharan 
Africa: Evidence from the demographic and health surveys. Soc Sci Med 2011;73(3):436-446. https://doi.
org/10.1016/j.socscimed.2011.05.042
28. Akwara PA, Noubary B, Lim Ah Ken P, et al. Who is the vulnerable child? Using survey data to identify 
children at risk in the era of HIV and AIDS. AIDS Care 2010;22(9):1066-1085. https://doi.org/10.10
80/09540121.2010.498878
29. Nannan N, Dorrington R, Laubscher R, et al. Under-5 Mortality Statistics in South Africa: Shedding 
Some Light on the Trends and Causes 1997 - 2007. Cape Town: MRC Burden of Disease Rsearch 
Unit, 2012. http://www.mrc.ac.za/sites/default/files/files/2017-05-26/MortalityStatisticsSA.pdf  (accessed 
25 Janu ary 2019).
30. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions 
for surveillance: African Region. 2005. https://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf?ua=1 
(accessed 10 July 2019).
31. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of 
severity. 2011. http://www.who.int/vmnis/indicators/haemoglobin.pdf (accessed 10 July 2019).
32. World Health Organization. WHO child growth standards. 2006. https://www.who.int/childgrowth/en/ 
(accessed 10 July 2019).
33. World Health Organization. Nutrition Landscape Information System (NLIS) country profile indica-
tors interpretation guide. 2010. https://www.who.int/nutrition/nlis_interpretation_guide.pdf (accessed 
10 July 2019).
Accepted 15 February 2019.
